Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study

Open access
Hilfiker-Kleiner, Denise, Haghikia, Arash, Berliner, Dominik, Vogel-Claussen, Jens, Schwab, Johannes, Franke, Annegret, Schwarzkopf, Marziel, Ehlermann, Philipp, Pfister, Roman, Michels, Guido, Westenfeld, Ralf, Stangl, Verena, Kindermann, Ingrid, Kühl, Uwe, Angermann, Christiane E., Schlitt, Axel, Fischer, Dieter, Podewski, Edith, Böhm, Michael, Sliwa, Karen, Bauersachs, Johann·2017·European Heart Journal

Abstract

AIMS: An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM. METHODS AND RESULTS: In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) ≤35% were randomly assigned to short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-term bromocriptine treatment (8W: 5 mg for 2 weeks followed by 2.5 mg for 6 weeks) in addition to standard heart failure therapy. Primary end point was LVEF change (delta) from baseline to 6 months assessed by magnetic resonance imaging. Bromocriptine was well tolerated. Left ventricular ejection fraction increased from 28 ± 10% to 49 ± 12% with a delta-LVEF of + 21 ± 11% in the 1W-group, and from 27 ± 10% to 51 ± 10% with a delta-LVEF of + 24 ± 11% in the 8W-group (delta-LVEF: P = 0.381). Full-recovery (LVEF ≥ 50%) was present in 52% of the 1W- and in 68% of the 8W-group with no differences in secondary end points between both groups (hospitalizations for heart failure: 1W: 9.7% vs. 8W: 6.5%, P = 0.651). The risk within the 8W-group to fail full-recovery after 6 months tended to be lower. No patient in the study needed heart transplantation, LV assist device or died. CONCLUSION: Bromocriptine treatment was associated with high rate of full LV-recovery and low morbidity and mortality in PPCM patients compared with other PPCM cohorts not treated with bromocriptine. No significant differences were observed between 1W and 8W treatment suggesting that 1-week addition of bromocriptine to standard heart failure treatment is already beneficial with a trend for better full-recovery in the 8W group. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, study number: NCT00998556.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehx355

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 348

Metadata

Authors
Hilfiker-Kleiner, D., Haghikia, A., Berliner, D., Vogel-Claussen, J., Schwab, J., Franke, A., Schwarzkopf, M., Ehlermann, P., Pfister, R., Michels, G., Westenfeld, R., Stangl, V., Kindermann, I., Kühl, U., Angermann, C. E., Schlitt, A., Fischer, D., Podewski, E., Böhm, M., Sliwa, K., & Bauersachs, J.
Venue
European Heart Journal
Published
2017-07-27
Volume
38
Issue
35
Pages
2671-2679
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2739987363
Cited by
348
References
1
FWCI
25.55
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. https://app.cochat.ai/papers/10.1093/eurheartj/ehx355
The paper
Hilfiker-Kleiner, D., Haghikia, A., Berliner, D., Vogel-Claussen, J., Schwab, J., Franke, A., Schwarzkopf, M., Ehlermann, P., Pfister, R., Michels, G., Westenfeld, R., Stangl, V., Kindermann, I., Kühl, U., Angermann, C. E., Schlitt, A., Fischer, D., Podewski, E., Böhm, M., . . . Bauersachs, J. (2017). Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehx355

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.